{"brief_title": "Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia", "brief_summary": "The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.", "condition": "Gram-Positive Bacterial Infections", "intervention_type": "Drug", "intervention_name": "Vancomycin, nafcillin, oxacillin, or cloxacillin", "description": "Vancomycin 1 Gram every 12 hr IV (intravenously) OR nafcillin, oxacillin, or cloxacillin 2 Grams every 6 hr IV (intravenously) for up to 14 days.", "arm_group_label": "Vancomycin, nafcillin, oxacillin, or cloxacillin", "other_name": "VIBATIV", "criteria": "Inclusion Criteria - Documented S. aureus bacteremia Exclusion Criteria - Patients who had received or would have received more than 72 hours of potentially effective systemic antistaphylococcal therapy within 7 days prior to randomization. The following agents were considered potentially effective antistaphylococcal therapy: antistaphylococcal penicillins (including nafcillin, oxacillin, or cloxacillin), cephalosporins, fluoroquinolones, glycopeptides (including vancomycin and teicoplanin) and linezolid", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00062647.xml"}